Daliresp: Advanced COPD Management for Improved Respiratory Function
| Product dosage: 500 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.95 | $58.48 (0%) | 🛒 Add to cart |
| 60 | $1.58 | $116.96 $94.60 (19%) | 🛒 Add to cart |
| 90 | $1.36 | $175.44 $122.12 (30%) | 🛒 Add to cart |
| 120 | $1.18 | $233.92 $141.90 (39%) | 🛒 Add to cart |
| 180 | $1.05
Best per tab | $350.88 $189.20 (46%) | 🛒 Add to cart |
Daliresp (roflumilast) is a selective phosphodiesterase-4 (PDE4) inhibitor indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. As an oral maintenance treatment, it targets underlying inflammation in the airways, offering a novel mechanism distinct from bronchodilators. It is not a rescue medication and does not replace bronchodilator therapy.
Features
- Active ingredient: Roflumilast 500 mcg
- Pharmaceutical form: Film-coated tablet
- Mechanism: Selective inhibition of phosphodiesterase-4 (PDE4)
- Administration: Oral, once daily
- Prescription status: Rx-only
- Manufacturer: AstraZeneca
Benefits
- Reduces frequency of moderate-to-severe COPD exacerbations
- Targets airway inflammation through PDE4 inhibition
- Convenient once-daily dosing regimen
- Complementary to bronchodilator therapy without interaction
- May improve lung function over time in appropriate patients
- Non-steroidal anti-inflammatory approach to COPD management
Common use
Daliresp is prescribed for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis in adults with a history of frequent exacerbations. It is specifically indicated to reduce the risk of COPD exacerbations. The medication is used as part of a comprehensive COPD management plan that typically includes bronchodilators. It is not indicated for the relief of acute bronchospasm or as rescue medication.
Dosage and direction
The recommended dosage is one 500 mcg tablet taken orally once daily, with or without food. Tablets should be swallowed whole and not crushed, chewed, or broken. Treatment should be initiated under medical supervision, and patients should be monitored for potential adverse effects, particularly weight loss and neuropsychiatric events. Dose adjustments are not recommended for elderly patients or those with mild to moderate hepatic impairment. The medication is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Precautions
Patients should be monitored for weight loss; if unexplained or clinically significant weight loss occurs, discontinuation should be considered. Neuropsychiatric events including insomnia, anxiety, depression, and suicidal ideation have been reported—prompt medical evaluation is recommended if such symptoms develop. Use with caution in patients with a history of depression or suicidal thoughts. Regular monitoring of liver function tests is recommended. Not recommended for use during pregnancy unless clearly needed. Breastfeeding is not recommended during treatment.
Contraindications
Moderate to severe liver impairment (Child-Pugh B or C). History of hypersensitivity to roflumilast or any component of the formulation. Not indicated for the treatment of acute bronchospasm. Not recommended in patients under 18 years of age.
Possible side effects
Common adverse reactions (≥2% and greater than placebo) include diarrhea, weight decrease, nausea, headache, insomnia, back pain, decreased appetite, and dizziness. Serious side effects may include psychiatric events including suicide, severe weight loss, and hypersensitivity reactions. Patients should report any persistent or severe symptoms to their healthcare provider immediately.
Drug interaction
Strong CYP3A4 inducers (rifampicin, phenobarbital, carbamazepine, phenytoin) may reduce roflumilast exposure and should be co-administered with caution. No clinically significant interactions have been observed with bronchodilators, corticosteroids, or theophylline. Caution is advised when co-administering with other CYP3A4 substrates.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If missed entirely for that day, the patient should resume the regular dosing schedule the following day. Do not double the dose to make up for a missed dose.
Overdose
In case of suspected overdose, symptomatic and supportive treatment is recommended. There is no specific antidote for roflumilast overdose. Medical attention should be sought immediately. Symptoms may include gastrointestinal disturbances, headache, dizziness, and other adverse effects similar to those seen at therapeutic doses but potentially more severe.
Storage
Store at room temperature (20-25°C or 68-77°F). Excursions permitted between 15-30°C (59-86°F). Keep in the original container with the lid tightly closed. Protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. The prescribing physician should be consulted for complete information about benefits, risks, and appropriate use. Individual results may vary based on patient-specific factors and disease severity.
Reviews
Clinical trials demonstrate that Daliresp significantly reduces the rate of moderate-to-severe COPD exacerbations compared to placebo. In pivotal studies, patients experienced approximately 15-20% reduction in exacerbation frequency. Many pulmonologists report positive outcomes in appropriate patient populations, particularly those with frequent exacerbations despite optimal bronchodilator therapy. Some clinicians note the need for careful patient selection and monitoring due to the side effect profile. Patient experiences vary, with some reporting improved quality of life due to reduced exacerbation frequency, while others may discontinue due to gastrointestinal side effects or weight loss.